Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Background Actinium-225 (²²⁵Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of ²²⁵Ac-PSMA RLT of mCRPC in a large cohort of patients treated at multiple centres across the world. Methods This retrospective study included patients treated at seven centres in Australia, India, Germany, and South Africa. We pooled data of consecutive patients of any age and Eastern Cooperative Oncology Group performance status with histopathologically confirmed adenocarcinoma of the prostate who were treated with one or more cycles of 8 MBq ²²⁵Ac-PSMA RLT administered intravenously for mCRPC. Previous lines of mCRPC treatment included taxane-based chemotherapy, androgen-receptor-axis inhibitors, lutetium-177 (¹⁷⁷Lu) PSMA RLT, and radium-223 dichloride. The primary outcomes were overall survival and progression-free survival.

SATHEKGE Mike;  LAWAL I;  BAL Chandrasekhar;  BRUCHERTSEIFER Frank;  BALLAL Sajana;  CARDACI Giuseppe;  DAVIS Cindy;  EIBER Mathias;  HEKIMSOY Türkay;  KNOESEN Otto;  KRATOCHWIL Clemens;  LENZO Nat P.;  MAHAPANE Johncy;  MASERUMULE Letjie;  MDLOPHANE Amanda;  MOKOALA K;  NDLOVU Honest;  PANT Vineet;  RATHKE H;  REED Janet;  SEN Ishita;  SINGH Aviral;  SOOD Ashwani;  TAUBER R;  THAKRAL Parul;  YADAV Madhav;  MORGENSTERN Alfred; 

2024-02-21

ELSEVIER SCIENCE INC

JRC135828

1470-2045 (online),   

https://www.sciencedirect.com/science/article/pii/S1470204523006381?via%3Dihub,    https://publications.jrc.ec.europa.eu/repository/handle/JRC135828,   

10.1016/S1470-2045(23)00638-1 (online),